| Literature DB >> 29187896 |
Yuanyuan Li1,2, Shunjie Liu2,3, Xun Zhao3, Ying Wang1,2, Jianhua Liu4, Xianhong Wang2,3, Lehui Lu1,2.
Abstract
Biodegradable polymeric nanomaterials can be directly broken down by intracellular processes, offering a desirable way to solve toxicity issues for cancer diagnosis and treatment. Among them, aliphatic polycarbonates are approved for application in biological fields by the United States Food and Drug Administration (FDA), however, high hydrophobicity, deficient functionality and improper degradation offer significant room for improvement in these materials.Entities:
Keywords: biodegradable; carbon dioxide; imaging agents; polycarbonate; renal clearance
Mesh:
Substances:
Year: 2017 PMID: 29187896 PMCID: PMC5706092 DOI: 10.7150/thno.21672
Source DB: PubMed Journal: Theranostics ISSN: 1838-7640 Impact factor: 11.556
Figure 1(A) Schematic illustration of the synthesis of APC-DTPA/Gd. (B) TEM of (left) APC and (right) APC-DTPA/Gd. (C) Energy-dispersive spectroscopy (EDS) mapping images of APC-DTPA/Gd.
Figure 2(A) T1-weighted MR images and (B) the relaxation rate of APC-DTPA/Gd vs. different concentrations of Gd3+. (C) TEM and (D) fluorescence spectra of APC-SN38. (E) The cell viability of HeLa cells in the presence of APC, free SN-38 and APC-SN38 under varied concentrations.
Figure 3(A) Cell viability of cells after incubation with increasing concentrations of APC and APC-DTPA/Gd. (B) Relative body weight of mice with different treatments. (C) H&E stained slices of major organs from mice treated with (top) saline, (middle) APC, and (bottom) APC-DTPA/Gd (The scale bar indicates 200 μm). (D) Blood analysis data and (E) liver-function test of different treatments (n=3).
Figure 4(A) The depolymerization process and ESI-MS spectra of APC-DTPA/Gd. (C) The 1H NMR and ESI-MS spectra of cyclic carbonate produced by APC depolymerization. (D) The depolymerization of APC and (E) Gd release from APC-DTPA/Gd under different conditions.
Figure 5Time dependent biodistribution of Gd3+ in organs of DTPA/Gd (A) and APC-DTPA/Gd (B). (C) The biodistribution of Gd3+ in the blood. (D) The concentration of Gd3+ in the urine after injection of APC-DTPA/Gd.
Figure 6In vivo T1-weighted MR images of a (A) large 4T1 tumor-bearing mouse before and after intravenous injection of DTPA-Gd and APC-DTPA/Gd. In vivo T1-weighted MR images and signal enhancement of mice bearing (B, C) small 4T1 and (D, E) A2780 tumors before and after intravenous injection of DTPA-Gd and APC-DTPA/Gd. The pseudo colors indicate the tumor sites.
Figure 7In vivo MR imaging of the liver (rectangles), bladder (circle) and kidney (ellipses) after intravenous injection of (A) APC-DTPA/Gd and (B) DTPA/Gd at different time points. In vivo MR signal varied after injection of (C) APC-DTPA/Gd and (D) DTPA/Gd at different time points.